Acumen Pharmaceuticals, Inc. ABOS
0.21 USD 0.00 (-1.71%)
Nov 5, 2026, 2:48 PM EST
0.1911 Day range 0.2199
0.1911 52-week range 3.60
- YTD
- -89.92%
- 1 year
- -89.53%
- Market cap
- 15.38M
- EPS (ttm)
- -1.55
- Shares out
- 60.08M
- Forward P/E
- -1.17
- YTD return
- -89.92%
- 1-year return
- -89.53%
- Volume
- 5.56M
- Avg volume
- 2.33M
- Open
- 0.2162
- Previous close
- 0.2163
- Day's range
- 0.1911 – 0.2199
- 52-week range
- 0.1911 – 3.60
- Beta
- 0.04
- Analysts
- Strong Buy
- Price target
- 10.80 (+4980.0%)
- Earnings date
- Aug 13, 2024
2Y -2.7919 (-93.06%)
Key statistics
- Enterprise value
- -59.21M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -41.69M
- Total cash
- 200.34M
- Total debt
- 29.99M
- Return on equity
- -32.83%
- Short % of float
- 3.10%
- 50-day average
- 2.48
- 200-day average
- 2.89
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 10.80 +4980.0% upside
Now 0.2126
- Target (low)
- 6.00
- Target (mean)
- 10.80
- Target (high)
- 15.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.36582.
Financials — quick view
ABOS Revenue — quarterly 0
ABOS Net income — quarterly -25.37M
ABOS EPS — quarterly -0.35
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.36 | -0.50 | -0.14 | -38.89% |
| Aug 13, 2024 | Jun 1, 2024 | -0.28 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.28 | -0.34 | -0.06 | -21.43% |
| May 14, 2024 | Mar 1, 2024 | -0.23 | -0.25 | -0.02 | -8.70% |
| May 14, 2024 | Mar 1, 2024 | -0.23 | — | — | — |
| Mar 26, 2024 | Dec 1, 2023 | -0.29 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | UBS | main | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 25, 2024 | Citigroup | init | — | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- acumenpharm.com
News
Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors 
12 Health Care Stocks Moving In Monday's After-Market Session 
12 Health Care Stocks Moving In Monday's Intraday Session 
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday 
BTIG Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $1 
12 Health Care Stocks Moving In Friday's After-Market Session - Citigroup Downgrades Acumen Pharmaceuticals to Neutral, Lowers Price Target to $1
12 Health Care Stocks Moving In Friday's Intraday Session 
Nasdaq Down Over 600 Points; Amazon Shares Fall Following Weak Q3 Results - 12 Health Care Stocks Moving In Friday's Pre-Market Session
Your note
Sign in to keep a note on ABOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARTON RUSSELL | Chief Operating Officer | Sale | Jan 17, 2024 | 96,867 |
| IVES JEFFREY L | Director | Sale | Aug 16, 2023 | 0 |
| MEISNER DEREK M | Officer | Sale | Jan 18, 2024 | 108,867 |
| O'CONNELL DANIEL JOSEPH | Chief Executive Officer | Sale | Jan 18, 2024 | 502,485 |
| RA CAPITAL MANAGEMENT, L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 20, 2023 | 0 |
| SIEMERS ERIC M.D. | Officer | Sale | Jan 17, 2024 | 117,576 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 24.85% | 14,932,063 | 26.73M | Sep 29, 2024 |
| Franklin Resources, Inc. | 5.91% | 3,549,069 | 6.35M | Sep 29, 2024 |
| Sands Capital Ventures, LLC | 5.69% | 3,417,075 | 6.12M | Sep 29, 2024 |
| Blackrock Inc. | 3.88% | 2,331,530 | 4.17M | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 3.83% | 2,300,059 | 4.12M | Sep 29, 2024 |
| FMR, LLC | 3.38% | 2,028,117 | 3.63M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Small Cap Growth Fund | 2.00% | 1,200,300 | 2.15M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.91% | 1,146,316 | 2.05M | Sep 29, 2024 |
| Fidelity Select Portfolios - Health Care | 1.90% | 1,140,000 | 2.04M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 1.68% | 1,009,063 | 1.81M | Oct 30, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 1.38% | 826,400 | 1.48M | Jul 30, 2024 |
| Fidelity Advisor Health Care Fund | 1.17% | 700,000 | 1.25M | Oct 30, 2024 |